#Isentress

Women in a global study began an HIV treatment regimen based on one of the two drugs after 20 weeks of gestation.

This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.

People who take integrase inhibitors are less likely to stop them due to health issues.

Tivicay (dolutegravir) is a next-generation integrase inhibitor.

This finding came from a larger report indicating that U.S. residents are increasingly taking drugs linked to such symptoms.

Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.

The process toward a creating a healthier lifestyle and discovering my genotype.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Immune reconstitution inflammatory syndrome (IRIS) can occur when individuals with low CD4 counts begin HIV treatment.

More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.

Until now, Isentress (raltegravir) had been available only as a twice-daily drug.

Researchers have succeeded in charting the structure of a tool central to HIV’s effort to splice its genetic code into a human cell’s DNA.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.